Bio-Techne (TECH)
NASDAQ: TECH · Life Sciences Tools & Services · Minneapolis, MN
Our rating: Neutral
Neutral reaffirmed at $72.83, moderate conviction, November 9, 2026.
Breaks if: The Neutral call turns Positive if Bio-Techne reports two consecutive quarters of organic revenue growth at or above 5% year over year, confirming the sector-cycle turn the multiple already implies. It turns Cautious if reported free cash flow falls below $55M in any single quarter (implying an annualized run rate below roughly $220M), signaling that the strong cash-conversion story is under real pressure — or if the stock falls more than 25% from today's $72.83 within twelve months without a corresponding recovery in reported growth.
Key figures
| Market value | $11.4B |
|---|---|
| Revenue, last 12 months | $1.2B |
| Net income, last 12 months | $172M |
| Free cash flow, last 12 months | $308M |
| Price to earnings | 66.4× |
| Free cash flow yield | 2.7% |
| Dividend yield | 0.4% |
| Operating margin | 19.6% |
| Return on equity | 8.3% |
| Beta to the S&P 500 | 0.98 |
| Volatility, annualized | 41.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $300M | 4.6% | $0.18 | $67M |
| June 30, 2026 | $321M | 1.3% | $0.35 | $87M |
| March 31, 2026 | $311M | −1.5% | $0.32 | $78M |
| December 31, 2025 | $296M | −0.4% | $0.24 | $76M |
| September 30, 2025 | $287M | −1.0% | $0.24 | $22M |
| June 30, 2025 | $317M | 3.5% | $-0.11 | $93M |
| March 31, 2025 | $316M | 4.2% | $0.14 | $31M |
| December 31, 2024 | $297M | 9.0% | $0.22 | $78M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.30B: Claude 62%, Gemini 88%, Mistral 70%
- Diluted earnings per share are at least $0.24: Claude 50%, Gemini 45%, Mistral 50%
- Free cash flow for the quarter is at least $0.08B: Claude 45%, Gemini 75%, Mistral 75%
10 ledger entries and 47 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.